The Role of Colchicine in Pericardial Syndromes

Posted on | Posted on John Murphy | Leave a Comment on The Role of Colchicine in Pericardial Syndromes

Authors: George Lazaros 1, Massimo Imazio 2, Antonio Brucato 3, Charalambos Vlachopoulos 1, Emilia Lazarou 1, Dimitrios Vassilopoulos 4, Dimitris Tousoulis 1PMID: 29336245 DOI: 10.2174/1381612824666180116101823 Curr Pharm Des . 2018;24(6):702-709. doi: 10.2174/1381612824666180116101823. Abstract Background: Colchicine is an old drug originally employed for the treatment of inflammatory disorders such as acute gout and familiar Mediterranean fever. Methods: In the past few decades, colchicine has been at the forefront of the pharmacotherapy of several […]

Acute pericarditis as a primary presentation of COVID-19

Posted on | Posted on John Murphy | Leave a Comment on Acute pericarditis as a primary presentation of COVID-19

Authors:Rajesh Kumar1, Jathinder Kumar1, Caroline Daly and Sadat Ali Edroos http://orcid.org/0000-0002-3267-63502 Abstract The COVID-19 pandemic is a highly contagious viral illness which conventionally manifests primarily with respiratory symptoms. We report a case whose first manifestation of COVID-19 was pericarditis, in the absence of respiratory symptoms, without any serious complications. Cardiac involvement in various forms is possible in COVID-19. We […]

Colchicine Treatment for Recurrent Pericarditis

Posted on | Posted on John Murphy | Leave a Comment on Colchicine Treatment for Recurrent Pericarditis

A Decade of Experience Authors: Y. Adler, Y. Finkelstein, J. Guindo, A. Rodriguez de la Serna, Y. Shoenfeld, A. Bayes-Genis, A. Sagie, A. Bayes de Luna and D. H. SpodickOriginally published2 Jun 1998 https://doi.org/10.1161/01.CIR.97.21.2183 Circulation. 1998;97:2183–2185 Abstract Background—The most troublesome complication of acute pericarditis is recurrent episodes of pericardial inflammation, occurring in 15% to 32% of cases. The cause of the recurrence is usually […]

Does COVID-19 Cause Hypertension?

Posted on | Posted on John Murphy | Leave a Comment on Does COVID-19 Cause Hypertension?

Authors: Mahmut Akpek, MD  December 10, 2021 Research Article https://doi.org/10.1177/00033197211053903 Abstract The coronavirus disease 2019 (COVID-19) outbreak remains a major public health challenge worldwide. The present study investigated the effect of COVID-19 on blood pressure (BP) during short term follow-up. A total of 211 consecutive COVID-19 patients who were admitted to Parkhayat Kutahya hospital were retrospectively screened. […]

Acute Kidney Injury in COVID-19

Posted on | Posted on John Murphy | Leave a Comment on Acute Kidney Injury in COVID-19

Authors: Marta Głowacka, Sara Lipka, Ewelina Młynarska,*Beata Franczyk, and Jacek RyszHajime Nagasu, Academic Editor Int J Mol Sci. 2021 Aug; 22(15): 8081.Published online 2021 Jul 28. doi: 10.3390/ijms22158081 PMCID: PMC8347536PMID: 34360866 Abstract COVID-19 is mainly considered a respiratory illness, but since SARS-CoV-2 uses the angiotensin converting enzyme 2 receptor (ACE2) to enter human cells, the kidney is also a target of the viral infection. […]

COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation?

Posted on | Posted on John Murphy | Leave a Comment on COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation?

Authors: Nicholas L. Li,1P. Toby Coates,2 and Brad H. Rovin1,∗ Kidney Int. 2021 Nov; 100(5): 959–965.Published online 2021 Sep 14. doi: 10.1016/j.kint.2021.09.002 PMCID: PMC8437826PMID: 34534551 To date, >4 billion doses of the various severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been administered worldwide in response to the coronavirus disease 2019 (COVID-19) pandemic. Even as widespread vaccination campaigns have contributed to […]

Electrocardiographic Changes in COVID-19 Patients: A Hospital-based Descriptive Study

Posted on | Posted on John Murphy | Leave a Comment on Electrocardiographic Changes in COVID-19 Patients: A Hospital-based Descriptive Study

Authors: Deepalakshmi Kaliyaperumal,1Kumar Bhargavi,2Karthikeyan Ramaraju,3Krishna S Nair,4Sudha Ramalingam,5 and Murali Alagesan6 Indian J Crit Care Med. 2022 Jan; 26(1): 43–48.doi: 10.5005/jp-journals-10071-24045PMCID:  PMC8783240PMID: 35110843 Abstract Background Coronavirus disease-2019 (COVID-19) infection is a multisystem disease not restricted to the lungs. It has a negative impact on the cardiovascular system by causing myocardial damage, vascular inflammation, plaque instability, and myocardial infarction. The presence […]

Five months post-covid, Nicole Murphy’s heart rate is still doing strange things

Posted on | Posted on John Murphy | Leave a Comment on Five months post-covid, Nicole Murphy’s heart rate is still doing strange things

Authors: Ariana Eunjung Cha February 21, 2022 Five months after being infected with the coronavirus, Nicole Murphy’s pulse rate is going berserk. Normally in the 70s, which is ideal, it has been jumping to 160, 170 and sometimes 210 beats per minute even when she is at rest — putting her at risk of a […]

Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination

Posted on | Posted on John Murphy | Leave a Comment on Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination

Authors: Aneel A. Ashrani, MD, MS1; Daniel J. Crusan, BS2; Tanya Petterson, MS2; et al JAMA Intern Med. 2022;182(1):80-83. doi:10.1001/jamainternmed.2021.6352 Recent reports1–4 suggest a possible association between Ad26.COV2.S (Johnson & Johnson/Janssen) COVID-19 vaccination and cerebral venous sinus thrombosis (CVST). Estimates of postvaccination CVST risk require accurate age- and sex-specific prepandemic CVST incidence rates; however, reported rates vary widely.5 We compared the age- and sex-specific CVST rates after […]

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities

Posted on | Posted on John Murphy | Leave a Comment on Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities

The I-TECH Randomized Clinical Trial Authors: Steven Chee Loon Lim, MRCP1; Chee Peng Hor, MSc2,3; Kim Heng Tay, MRCP4; et al JAMA Intern Med. Published online February 18, 2022. doi:10.1001/jamainternmed.2022.0189 Key Points Question  Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities? Findings  In this open-label randomized clinical trial […]